Libreville

Researchers are collecting detailed information about children with cancer who are treated at pediatric oncology units in French-speaking Africa. This registry aims to provide accurate data on the number of cases, disease stage, treatments, and outcomes to help improve pediatric cancer care and support local and national health planning. The project focuses on children and adolescents under 18 years old diagnosed with any type of cancer. The data includes demographic and socioeconomic details along with clinical status and treatment results. Information on vital status, treatment abandonment, and loss to follow-up is also gathered. Data is entered locally into an online system called REDCap and securely stored by the IT department at Gustave ROUSSY in Paris-Villejuif. Participants are children under 18 who come to participating hospitals for cancer treatment. Researchers track the number of children suspected of having cancer, their health status, treatment progress, and survival over any 12-month period. This ongoing registry helps monitor outcomes and supports efforts to improve pediatric oncology services in the region.

Researchers are evaluating the effectiveness and safety of different anti-malarial drugs in adults, adolescents, and children with uncomplicated Plasmodium falciparum malaria. This study aims to assess how well these medications kill the malaria parasite and their potential to cure the infection, while also studying how well the drugs are tolerated and how they behave in the body to determine appropriate dosing for future research. The study is a multi-part, multi-center platform trial in Phase 2. Participants may receive one or a combination of oral anti-malarial agents, including INE963, KAE609 (Cipargamin), KLU156 (a combination of KAF156 and lumefantrine), or the standard of care drug Coartem. Treatments are given either alone or in combination, and different parts of the study include specific age and weight groups to evaluate these drugs. The study includes several parts, with participants receiving assigned treatments and being monitored closely. During the study, participants will have their parasite levels checked up to day 7 to measure how quickly the infection clears. On day 29, researchers will evaluate the clinical and parasitological response using polymerase chain reaction (PCR) tests. Participants will undergo various assessments including parasite counts, vital signs, and safety monitoring. The study involves detailed follow-up to assess treatment effectiveness and safety over time, with the total participation duration depending on the study part.